Yes, Lurbinectedin can be used in combination with other treatments. Lurbinectedin is a novel selective inhibitor of oncogenic transcription. It works by binding to DNA and inhibiting the transcriptional activity of oncogenic fusion proteins, which can lead to tumor cell death [1].

The drug has been studied in combination with other treatments, such as immunotherapy and chemotherapy, to assess its safety and efficacy. For instance, a phase Ib/II study investigated the combination of Lurbinectedin and the anti-PD-L1 monoclonal antibody, pembrolizumab, in patients with small cell lung cancer (SCLC) [2]. The results showed that the combination was well-tolerated and demonstrated encouraging anti-tumor activity.

Moreover, a phase III study is currently ongoing to evaluate the efficacy and safety of Lurbinectedin in combination with doxorubicin versus standard treatment in patients with relapsed small cell lung cancer (SCLC) [3].

In summary, Lurbinectedin can be used in combination with other treatments, such as immunotherapy and chemotherapy, and is currently being studied in clinical trials to assess its safety and efficacy.

Sources:

1. <https://www.drugs.com/ppa/lurbinectedin.html>
2. <https://ascopubs.org/doi/abs/10.1200/JCO.19.01303>
3. <https://clinicaltrials.gov/ct2/show/NCT04089336>
4. <https://www.drugpatentwatch.com/drugs/lurbinectedin>